There are many things happening in the world of myocarditis and pericarditis, and all of them are looking very positive for patients. Cardiol Therapeutics has been working on Clinical Trials for both of these diseases and so far the outcomes are looking to be very helpful for those suffering, especially with recurrent pericarditis.
The ARCHER Trial, currently in Phase II, is working on a treatment for acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in those less than 35 years old.
The MAVERIC Trial, has just enrolled their first patient in their pivotal Phase III trial for Recurrent Pericarditis. CardiolRx is the drug they are working on for the treatment of pericarditis/recurrent pericarditis and the FDA has granted Orphan Drug Designation to CardiolRx for use. “Orphan Drug status” means that the drug is intended to treat, diagnose, or prevent a rare disease or condition. The FDA gives certain benefits to drug companies developing treatments for rare diseases, that are not as attractive to pharmaceutical companies because of limited market potential.
The MAVERIC Phase II trial has demonstrated that patients experienced marked and rapid reductions in both pericarditis pain and inflammation that were maintained throughout the study. In addition, the results demonstrated a substantial reduction in pericarditis episodes per year, and shown to be safe and well tolerated in a patient population who presented with a high degree of disease burden.
Cardiol Therapeutics has just enrolled their first patient into their Phase III MAVERIC Trial in Recurrent Pericarditis.
Please read more about this by clicking on the link below.
